Yu-Chuan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yu-Chuan Liu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Steven M. Chan
Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, ON
40 shared publications - Anne Tierens
21Laboratory Medicine Program, University Health Network and University of Toronto, Toronto, Canada
39 shared publications - David L. Dai
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
39 shared publications - Dhanoop Manikoth Ayyathan
Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
39 shared publications - Mark David Minden
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
39 shared publications - Mohsen Hosseini
Princess Margaret Cancer Centre, Toronto, ON, Canada
39 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
STAT5 consensus binding motif around HOX genes
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
STAT5 consensus binding motif around HOX genes
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Fig. S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Supplementary Figure 5 and legend
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig. S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Supplementary Figure 5 and legend
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Fig. S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Supplementary Figure 2 and legend
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig. S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Supplementary Figure 2 and legend
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Characteristics of the primary AML samples
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Characteristics of the primary AML samples
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Fig. S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Supplementary Figure 3 and legend
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig. S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Supplementary Figure 3 and legend
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
OCImIDH1N WES exonic nonsynonymous variants (DP>100)
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
OCImIDH1N WES exonic nonsynonymous variants (DP>100)
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Fig. S6 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Supplementary Figure 6 and legend
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig. S6 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Supplementary Figure 6 and legend
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Fig. S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Supplementary Figure 4 and legend
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig. S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Supplementary Figure 4 and legend
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
OCImIDH1N-R WES exonic nonsynonymous variants (DP>100)
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
OCImIDH1N-R WES exonic nonsynonymous variants (DP>100)